Zhen‐Huan Hu

3.3k total citations · 1 hit paper
44 papers, 955 citations indexed

About

Zhen‐Huan Hu is a scholar working on Oncology, Hematology and Pathology and Forensic Medicine. According to data from OpenAlex, Zhen‐Huan Hu has authored 44 papers receiving a total of 955 indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Oncology, 14 papers in Hematology and 9 papers in Pathology and Forensic Medicine. Recurrent topics in Zhen‐Huan Hu's work include CAR-T cell therapy research (25 papers), Acute Myeloid Leukemia Research (10 papers) and Lymphoma Diagnosis and Treatment (9 papers). Zhen‐Huan Hu is often cited by papers focused on CAR-T cell therapy research (25 papers), Acute Myeloid Leukemia Research (10 papers) and Lymphoma Diagnosis and Treatment (9 papers). Zhen‐Huan Hu collaborates with scholars based in United States, United Kingdom and Canada. Zhen‐Huan Hu's co-authors include Corey Cutler, Joseph H. Antin, Wael Saber, Donna Neuberg, Stephen R. Spellman, Robert Redd, R. Coleman Lindsley, Brenton G. Mar, Michael R. Verneris and Stephanie J. Lee and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Zhen‐Huan Hu

38 papers receiving 946 citations

Hit Papers

Prognostic Mutations in M... 2017 2026 2020 2023 2017 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation
    2017 473 citations R. Coleman Lindsley, Wael Saber et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Zhen‐Huan Hu United States 12 617 335 230 211 150 44 955
Vladan Vučinić Germany 18 518 0.8× 333 1.0× 153 0.7× 177 0.8× 230 1.5× 105 934
Sumithira Vasu United States 13 424 0.7× 380 1.1× 120 0.5× 144 0.7× 231 1.5× 78 851
Kathleen Dorritie United States 15 179 0.3× 466 1.4× 181 0.8× 166 0.8× 216 1.4× 45 773
Zhengming Jin China 15 325 0.5× 270 0.8× 72 0.3× 124 0.6× 127 0.8× 98 660
Édouard Forcade France 18 674 1.1× 441 1.3× 195 0.8× 138 0.7× 372 2.5× 105 1.2k
Zeba N. Singh United States 15 497 0.8× 485 1.4× 130 0.6× 360 1.7× 182 1.2× 54 984
Mahasweta Gooptu United States 16 432 0.7× 201 0.6× 111 0.5× 123 0.6× 192 1.3× 66 683
Samer A. Srour United States 15 316 0.5× 369 1.1× 81 0.4× 136 0.6× 154 1.0× 98 682
Alexey Maschan Russia 17 477 0.8× 236 0.7× 120 0.5× 147 0.7× 231 1.5× 137 854
Sigal Grisariu Israel 14 239 0.4× 246 0.7× 179 0.8× 161 0.8× 86 0.6× 48 742

Countries citing papers authored by Zhen‐Huan Hu

Since Specialization
Citations

This map shows the geographic impact of Zhen‐Huan Hu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zhen‐Huan Hu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zhen‐Huan Hu more than expected).

Fields of papers citing papers by Zhen‐Huan Hu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zhen‐Huan Hu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zhen‐Huan Hu. The network helps show where Zhen‐Huan Hu may publish in the future.

Co-authorship network of co-authors of Zhen‐Huan Hu

This figure shows the co-authorship network connecting the top 25 collaborators of Zhen‐Huan Hu. A scholar is included among the top collaborators of Zhen‐Huan Hu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zhen‐Huan Hu. Zhen‐Huan Hu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wang, Limin, Wenjuan Li, Wei Zhao, et al.. (2025). Genome-Wide Identification and Expression Profiling of Dehydration-Responsive Element-Binding Family Genes in Flax (Linum usitatissimum L.). International Journal of Molecular Sciences. 26(7). 3074–3074. 1 indexed citations
2.
Nikiforow, Sarah, Michael K. Mansour, Zhen‐Huan Hu, et al.. (2024). Tocilizumab not associated with increased infection risk after CAR T-cell therapy: implications for COVID-19?. UNC Libraries.
3.
4.
Pasquini, Marcelo C., Richard T. Maziarz, Zhen‐Huan Hu, et al.. (2024). “Don't keep me waiting”: estimating the impact of reduced vein-to-vein time on lifetime US 3L+ LBCL patient outcomes. Blood Advances. 8(13). 3519–3527.
5.
Strouse, Christopher, Umar Farooq, Roni Shouval, et al.. (2024). Predictors of Early Safety Outcomes with Axicabtagene Ciloleucel (axi-cel) in Patients with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL). Blood. 144(Supplement 1). 609–609.
6.
Ahmed, Nausheen, Mehdi Hamadani, Natalie S. Grover, et al.. (2023). S220: REAL-WORLD OUTCOMES OF BREXUCABTAGENE AUTOLEUCEL (BREXU-CEL) FOR RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA: A CIBMTR SUBGROUP ANALYSIS BY PRIOR TREATMENT. HemaSphere. 7(S3). e43327c1–e43327c1. 1 indexed citations
7.
Locke, Frederick L., Zhen‐Huan Hu, Tanya Siddiqi, et al.. (2022). Real-World Impact of Time from Leukapheresis to Infusion (Vein-to-Vein Time) in Patients with Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) Treated with Axicabtagene Ciloleucel. Blood. 140(Supplement 1). 7512–7515. 13 indexed citations
8.
Locke, Frederick L., Tanya Siddiqi, Caron A. Jacobson, et al.. (2022). Real-world outcomes of axicabtagene ciloleucel (Axi-cel) for the treatment of large B-cell lymphoma (LBCL) by race and ethnicity.. Journal of Clinical Oncology. 40(16_suppl). 7571–7571. 8 indexed citations
9.
10.
11.
12.
13.
Locke, Frederick L., Caron A. Jacobson, Long Ma, et al.. (2021). Real-World Outcomes of Axicabtagene Ciloleucel (Axi-cel) for the Treatment of Large B-Cell Lymphoma (LBCL): Impact of Age and Specific Organ Dysfunction. Blood. 138(Supplement 1). 530–530. 11 indexed citations
14.
Myllymäki, Mikko, Robert Redd, Christopher R. Reilly, et al.. (2020). Short telomere length predicts nonrelapse mortality after stem cell transplantation for myelodysplastic syndrome. Blood. 136(26). 3070–3081. 23 indexed citations
15.
16.
Pasquini, Marcelo C., Frederick L. Locke, Alex F. Herrera, et al.. (2019). Post-Marketing Use Outcomes of an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, Axicabtagene Ciloleucel (Axi-Cel), for the Treatment of Large B Cell Lymphoma (LBCL) in the United States (US). Blood. 134(Supplement_1). 764–764. 72 indexed citations
17.
Hu, Zhen‐Huan, Robert Peter Gale, & Mei‐Jie Zhang. (2019). Direct adjusted survival and cumulative incidence curves for observational studies. Bone Marrow Transplantation. 55(3). 538–543. 13 indexed citations
18.
Myllymäki, Mikko, Robert Redd, Corey Cutler, et al.. (2018). Telomere Length and Telomerase Complex Mutations Predict Fatal Treatment Toxicity after Stem Cell Transplantation in Patients with Myelodysplastic Syndrome. Blood. 132(Supplement 1). 796–796. 3 indexed citations
19.
Lindsley, R. Coleman, Wael Saber, Brenton G. Mar, et al.. (2017). Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation. New England Journal of Medicine. 376(6). 536–547. 473 indexed citations breakdown →
20.
Feo, Emma De, Benedetto Simone, P. Gallì, et al.. (2011). p73 G4C14-to-A4T14 gene polymorphism and interaction with p53 exon 4 Arg72Pro on cancer susceptibility: a meta-analysis of the literature. Mutagenesis. 27(3). 267–273. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Vladan Vučinić Breakdown of academic impact, for papers by Sumithira Vasu Breakdown of academic impact, for papers by Kathleen Dorritie Breakdown of academic impact, for papers by Zhengming Jin Breakdown of academic impact, for papers by Édouard Forcade Breakdown of academic impact, for papers by Zeba N. Singh Breakdown of academic impact, for papers by Mahasweta Gooptu Breakdown of academic impact, for papers by Samer A. Srour Breakdown of academic impact, for papers by Alexey Maschan Breakdown of academic impact, for papers by Sigal Grisariu
Rankless by CCL
2026